Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zaragoza, Sophia
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Active, not recruiting	2/3	186	NA	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	05/25	05/25
Ruiz, Monica
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC	Active, not recruiting	2	60	US	Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo	Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.	Primary Biliary Cholangitis	11/24	02/25
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25
Golez, Jerica
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
NCT05104853: Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects with Primary Biliary Cholangitis	Active, not recruiting	1/2	42	US	CNP-104, Placebo	COUR Pharmaceutical Development Company, Inc.	Primary Biliary Cholangitis	01/26	01/26